Centessa Pharmaceuticals (CNTA) Amortization of Deferred Charges (2025 - 2026)

Centessa Pharmaceuticals (CNTA) reported Amortization of Deferred Charges of $345000.0 for Q1 2026, up 10.58% year-over-year from $312000.0 in Q1 2025, and up 23.66% quarter-over-quarter from $279000.0 in Q4 2025.

Centessa Pharmaceuticals (CNTA) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends

Centessa Pharmaceuticals (CNTA) has 2 years of Amortization of Deferred Charges data on file, last reported at $345000.0 in Q1 2026.

  • Amortization of Deferred Charges for Q1 2026 came in at $345000.0, up 10.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 280.77% YoY), and the FY2025 annual result was $1.2 million, changed N/A from the prior year.
  • Amortization of Deferred Charges rose to $345000.0 in Q1 2026 per CNTA's latest filing, from $279000.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $345000.0 in Q1 2026 and troughed at $271000.0 in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn -
7 Psyence Biomedical 229.39 Bn 229.38 Bn -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn
9 Abivax 90.15 Bn 90.15 Bn -
10 Centessa Pharmaceuticals 6.10 Bn 6.10 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 345,000.00
Mar 31, 2026 345,000.00
Dec 31, 2025 279,000.00
Dec 31, 2025 279,000.00
Sep 30, 2025 271,000.00
Sep 30, 2025 271,000.00
Jun 30, 2025 293,000.00
Jun 30, 2025 293,000.00
Mar 31, 2025 312,000.00
Mar 31, 2025 312,000.00